Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab for Relapsed/Refractory Large B-Cell Lymphomas Before Definitive Lymphoma-Directed Therapies
NCT06784726Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Sep 2025
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of odronextamab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Washington. Started Sep 2025; status: recruiting.
02
Drugs
odronextamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06784726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784726.